| ID Source | ID |
|---|---|
| PubMed CID | 44142097 |
| CHEMBL ID | 564568 |
| CHEBI ID | 92699 |
| SCHEMBL ID | 1774580 |
| Synonym |
|---|
| triazolothiadiazine, 35 |
| smr001317670 |
| bdbm30041 |
| MLS002264368 |
| CHEMBL564568 |
| HMS2194K23 |
| NCGC00167104-01 |
| HMS3338N10 |
| SCHEMBL1774580 |
| CHEBI:92699 |
| 6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2-fluorophenyl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine |
| Q27164401 |
| iqkdoqfeiskley-uhfffaoysa-n |
| Class | Description |
|---|---|
| triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3535 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 (µMol) | 0.0530 | 0.0000 | 1.0680 | 10.0000 | AID1799059; AID425676 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cAMP catabolic process | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| signal transduction | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| sensory perception of smell | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| regulation of protein kinase A signaling | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| cellular response to xenobiotic stimulus | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| cAMP-mediated signaling | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| 3',5'-cyclic-AMP phosphodiesterase activity | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| protein binding | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| cAMP binding | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| metal ion binding | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| 3',5'-cyclic-GMP phosphodiesterase activity | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleoplasm | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| cytosol | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| plasma membrane | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| membrane | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| ruffle membrane | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| perinuclear region of cytoplasm | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| perinuclear region of cytoplasm | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| cytosol | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| nucleus | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID425676 | Inhibition of human PDE4A by IMAP fluorescence polarization technology | 2009 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13 | Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors. |
| AID1799059 | PDE4A Inhibition Assay from Article 10.1016/j.bmcl.2009.01.057: \\Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.\\ | 2009 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13 | Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||